V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330010095 | 330004346 | 1.89 | null | Neo-adjuvant (N) | 2013-11-14 | 2014-05-03 | MAP | 02 | N | 330011497 | MAP |
| 330010096 | 330004350 | 1.65 | 63.4 | Palliative (P) | 2014-02-12 | 2014-03-03 | PAM x 2 post-surgery (cycles 3&4) | 2 | N | 330011499 | MAP |
| 330010097 | 330004351 | 1.77 | 75 | Palliative (P) | 2013-10-05 | 2013-10-09 | CISPLATIN + FLUOROURACIL | 2 | N | 330011502 | CISPLATIN + FLUOROURACIL |
| 330010098 | 330004352 | 1.64 | 70.5 | Palliative (P) | 2017-07-17 | 2017-09-09 | MAP | 2 | N | 330011513 | MAP |
| 330010099 | 330008376 | 1.75 | 77.7 | Curative (C) | 2014-11-02 | 2014-11-05 | OST Euramos 1 Closed Trial - AP | Y | N | 330011517 | MAP |
| 330010100 | 330004358 | 0 | null | Curative (C) | 2014-01-05 | 2014-03-02 | OST Euramos 1 Closed Trial - AP | N | N | 330011529 | MAP |
| 330010101 | 330008380 | 1.62 | 57.2 | Palliative (P) | 2015-10-24 | 2015-11-10 | Docetaxel + Gemcitabine (prior RT) | N | N | 330011562 | DOCETAXEL + GEMCITABINE |
| 330010102 | 330004364 | 0 | 79.2 | Curative (C) | 2017-12-17 | 2017-12-17 | CETUXIMAB | N | N | 330011598 | CETUXIMAB |
| 330010103 | 330004368 | 1.91 | null | Neo-adjuvant (N) | 2018-03-30 | 2018-05-08 | Etoposide + Ifosfamide (5 days) | N | N | 330011603 | ETOPOSIDE + IFOSFAMIDE |
| 330010104 | 330004370 | 1.6 | 88.8 | Curative (C) | 2016-08-26 | 2016-08-26 | CISPLATIN + FLUOROURACIL | 2 | N | 330011606 | CISPLATIN + FLUOROURACIL |
| 330010105 | 330004372 | 0 | 85.1 | Palliative (P) | 2014-04-11 | 2014-04-11 | CISPLATIN + FLUOROURACIL | N | N | 330011640 | CISPLATIN + FLUOROURACIL |
| 330010106 | 330004374 | 0 | 57.7 | Disease modification (D) | 2017-03-25 | 2017-04-16 | Methotrexate High Dose (3g/m2) | N | N | 330011643 | METHOTREXATE HIGH DOSE |
| 330010107 | 330012424 | 1.83 | 81 | Disease modification (D) | null | 2015-05-15 | Rituximab | null | null | 330011654 | RITUXIMAB |
| 330010108 | 330004377 | 1.81 | 90.8 | Neo-adjuvant (N) | 2017-05-05 | 2017-08-02 | Etoposide + Ifosfamide (3 days) | N | N | 330011658 | ETOPOSIDE + IFOSFAMIDE |
| 330010109 | 330010552 | null | 79.4 | Palliative (P) | 2018-05-13 | 2018-08-01 | Docetaxel + Gemcitabine (prior RT) | N | N | 330011667 | DOCETAXEL + GEMCITABINE |
| 330010110 | 330004379 | 1.8 | 54.8 | Disease modification (D) | 2013-12-30 | 2014-01-02 | OST Euramos 1 Closed Trial - M | 02 | N | 330011676 | METHOTREXATE HIGH DOSE |
| 330010111 | 330008387 | 1.64 | 106.2 | Curative (C) | 2015-01-21 | 2015-02-01 | Cisplatin +Fluorouracil (3 wk) | 02 | N | 330011679 | CISPLATIN + FLUOROURACIL |
| 330010112 | 330004381 | 1.63 | 65 | null | 2014-03-13 | 2014-05-22 | CISPLATIN + FLUOROURACIL | 2 | Y | 330011679 | CISPLATIN + FLUOROURACIL |
| 330010113 | 330004384 | 0 | null | Disease modification (D) | 2016-06-02 | 2016-06-02 | Rituximab | null | null | 330011689 | RITUXIMAB |
| 330010114 | 330008391 | null | 68 | Not known (9) | 2018-05-08 | 2018-05-14 | Carboplatin AUC 6 - 10 | N | N | 330011692 | CARBOPLATIN |
| 330010115 | 330004388 | 1.72 | 76 | Palliative (P) | 2015-09-23 | 2015-10-07 | Carboplatin AUC 2 - 5 | N | N | 330011701 | CARBOPLATIN |
| 330010116 | 330008392 | 1.73 | 85.699 | Curative (C) | 2013-05-16 | 2013-06-19 | Rituximab | N | null | 330011707 | RITUXIMAB |
| 330010117 | 330004390 | null | 68.1 | Neo-adjuvant (N) | 2014-08-25 | 2014-10-03 | Etoposide + Ifosfamide (3 days) | N | N | 330011730 | ETOPOSIDE + IFOSFAMIDE |
| 330010118 | 330004394 | 1.76 | 76.2 | Palliative (P) | 2015-02-06 | 2015-02-10 | Rituximab (SUBCUTANEOUS Maintenance) | N | null | 330011745 | RITUXIMAB |
| 330010119 | 330004395 | null | 79.9 | Palliative (P) | 2017-03-07 | 2017-04-03 | Carboplatin AUC 2 - 5 | N | N | 330011757 | CARBOPLATIN |
| 330010120 | 330004396 | 1.64 | null | Palliative (P) | 2016-04-03 | 2016-04-24 | Cetuximab 7 day (>Cycle 2) | 02 | N | 330011761 | CETUXIMAB |
| 330010121 | 330004396 | 1.7 | 0 | Palliative (P) | 2017-05-11 | 2017-09-03 | PAM x 2 post-surgery (cycles 3&4) | N | N | 330011761 | MAP |
| 330010122 | 330004401 | 1.85 | 57 | Curative (C) | 2014-07-03 | 2014-07-21 | CETUXIMAB | N | N | 330011779 | CETUXIMAB |
| 330010123 | 330004402 | null | 101.3 | Palliative (P) | null | 2017-11-29 | DOCETAXEL + GEMCITABINE | null | null | 330011783 | DOCETAXEL + GEMCITABINE |
| 330010124 | 330004405 | null | 95.3 | Adjuvant (A) | 2014-06-02 | 2014-06-03 | Rituximab | N | Y | 330011786 | RITUXIMAB |
| 330010125 | 330004408 | 1.76 | null | Disease modification (D) | 2015-04-13 | 2015-01-15 | OST Euramos 1 Closed Trial - M | 2 | Y | 330011787 | METHOTREXATE HIGH DOSE |
| 330010126 | 330004411 | 1.56 | 116.2 | Palliative (P) | 2014-10-11 | 2014-10-15 | Cetuximab 7 day (Cycle 1) | N | N | 330011789 | CETUXIMAB |
| 330010127 | 330008403 | 1.56 | 58 | Curative (C) | 2015-08-14 | 2015-09-03 | Rituximab | N | N | 330011807 | RITUXIMAB |
| 330010128 | 330004414 | 1.65 | 60.7 | Curative (C) | 2017-01-08 | 2017-01-09 | OST Euramos 1 Closed Trial - M | 2 | N | 330011813 | METHOTREXATE HIGH DOSE |
| 330010129 | 330004418 | 1.72 | 72.5 | Curative (C) | 2016-08-24 | 2017-02-22 | Carboplatin AUC 2 - 5 | N | N | 330011824 | CARBOPLATIN |
| 330010130 | 330004419 | 0 | 77.7 | null | 2016-11-09 | 2016-11-23 | Rituximab | 1 | N | 330011825 | RITUXIMAB |
| 330010131 | 330004421 | 1.75 | 72.3 | Palliative (P) | 2014-11-10 | 2015-03-10 | CISPLATIN + FLUOROURACIL | N | N | 330011835 | CISPLATIN + FLUOROURACIL |
| 330010132 | 330004422 | 1.59 | 57.2 | null | 2016-07-10 | 2016-07-24 | PAM x 2 post-surgery (cycles 3&4) | N | N | 330011841 | MAP |
| 330010133 | 330012427 | 1.85 | 95.6 | Palliative (P) | 2014-05-20 | 2014-05-21 | Cisplatin +Fluorouracil (3 wk) | N | null | 330011849 | CISPLATIN + FLUOROURACIL |
| 330010134 | 330012427 | 1.73 | 92 | Adjuvant (A) | 2014-02-17 | 2014-12-21 | OST Euramos 1 Closed Trial - AP | null | N | 330011849 | MAP |
| 330010135 | 330012428 | 1.64 | 75.9 | Palliative (P) | 2014-03-08 | 2014-03-13 | Rituximab (SUBCUTANEOUS Maintenance) | N | N | 330011872 | RITUXIMAB |
| 330010136 | 330004426 | 1.83 | 65.5 | Curative (C) | 2017-11-17 | 2017-12-27 | Rituximab (Maintenance) | 02 | N | 330011881 | RITUXIMAB |
| 330010137 | 330004427 | 1.73 | 67.1 | Curative (C) | 2014-11-27 | 2015-04-09 | CETUXIMAB | N | N | 330011902 | CETUXIMAB |
| 330010138 | 330004430 | 1.59 | 46.4 | Palliative (P) | 2016-02-10 | 2016-02-14 | CISPLATIN + FLUOROURACIL | N | N | 330011916 | CISPLATIN + FLUOROURACIL |
| 330010139 | 330004433 | 1.65 | 55.2 | Curative (C) | 2014-01-22 | 2014-02-03 | CETUXIMAB | N | N | 330011931 | CETUXIMAB |
| 330010140 | 330012429 | 1.65 | 56.7 | Curative (C) | 2017-02-23 | 2017-03-04 | EURAMOS TRIAL | 1 | N | 330011933 | EURAMOS TRIAL |
| 330010141 | 330013249 | 0 | 69.9 | Curative (C) | 2014-05-12 | 2014-05-12 | Bendamustine+Rituximab(Sub Courses) | 02 | N | 330011940 | BENDAMUSTINE + RITUXIMAB |
| 330010142 | 330013249 | 1.75 | 85.5 | Curative (C) | 2016-01-09 | 2016-01-31 | Carboplatin + Etoposide IV 3 day | null | Y | 330011940 | CARBOPLATIN + ETOPOSIDE |
| 330010143 | 330004435 | 1.78 | 87.9 | Palliative (P) | 2019-01-14 | 2019-01-19 | BENDAMUSTINE + RITUXIMAB | 2 | N | 330011956 | BENDAMUSTINE + RITUXIMAB |
| 330010144 | 330004437 | 1.75 | 73.8 | Curative (C) | 2016-03-03 | 2016-03-05 | ALL UKALL2011 Del Int A Pt1 (PAsp) | N | N | 330011960 | UKALL2011 |